CTLA4 haploinsufficiency caused by a novel heterozygous splice site mutation
-
Published:2022-06-01
Issue:2
Volume:9
Page:40-44
-
ISSN:2292-5937
-
Container-title:LymphoSign Journal
-
language:en
-
Short-container-title:LymphoSign Journal
Author:
Garkaby Jenny11, Abrego Fuentes Laura Edith11, Willett Pachul Jessica11, Vong Linda11
Affiliation:
1. Division of Clinical Immunology and Allergy, Department of Paediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON
Abstract
Background: Cytotoxic T lymphocyte-associated antigen-4 (CTLA4) haploinsufficiency is characterized by a variety of phenotypes, ranging from autoimmune disorders, enteropathy, fatal combined immunodeficiency, as well as lymphoproliferation and malignancy. Aim: To broaden the genotypic spectrum and clinical presentations of patients with CTLA4 variants. Methods: We evaluated a female patient with autoimmunity and lymphopenia. Immune workup and whole exome sequencing (WES) were performed. Results: The proband presented at 11 years of age with hypothyroidism and later developed Evans syndrome, alopecia, eczema, and lymphocytic interstitial pneumonia. Immune evaluation revealed T, B, and NK lymphopenia with normal humoral immunity. Following a negative genetic panel for autoimmune lymphoproliferative syndrome (ALPS), WES analysis identified a novel heterozygous intronic variant predicted in-silico to cause skipping of exon 2 of the CTLA4 gene. Conclusion: A novel heterozygous mutation in CTLA4 caused variable presentations of immune dysregulation, one of the hallmarks of CTLA4 haploinsufficiency. Statement of Novelty: We herein report a novel mutation in CTLA4 resulting in various features of autoimmunity.
Publisher
LymphoSign Journal Limited Partnership
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference12 articles.
1. Cunningham-Rundles, C. 2010. How I treat common variable immune deficiency. Blood, 116(1): 7 [online]. Available from /pmc/articles/PMC2904582/ [accessed 5 April 2022]. PMID: 20332369. doi: 10.1182/blood-2010-01-254417. 2. Therapeutic options for CTLA-4 insufficiency 3. A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer 4. Immune dysregulation in human subjects with heterozygous germline mutations in
CTLA4 5. Lo, B., Zhang, K., Lu, W., Zheng, L., Zhang, Q., Kanellopoulou, C., Zhang, Y., Liu, Z., Fritz, J.M., Marsh, R., Husami, A., Kissell, D., Nortman, S., Chaturvedi, V., Haines, H., Young, L.R., Mo, J., Filipovich, A.H., Bleesing, J.J., Mustillo, P., Stephens, M., Rueda, C.M., Chougnet, C.A., Hoebe, K., McElwee, J., Hughes, J.D., Karakoc-Aydiner, E., Matthews, H.F., Price, S., Su, H.C., Rao, V.K., Lenardo, M.J., and Jordan, M.B. 2015. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science (New York, N.Y.) 349(6246): 436–440 [online]. Available from https://pubmed.ncbi.nlm.nih.gov/26206937/ [accessed 30 April 2022]. doi: 10.1126/science.aaa1663.
|
|